Expression of c‐erbB‐2 oncoprotein in salivary gland tumours: An immunohistochemical study

Kernohan, Neil M.; Blessing, K.; King, G.; Corbett, Ian; Miller, Iain D.

doi:10.1002/path.1711630113

Cited by 62 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shrestha et al (26) and Sugano et al (27) found HER2 expression in only 4.5 (1/22) and 0% (0/9), respectively, of the studied mucoepidermoid carcinomas. Kernohan et al (28) reported positive immunostaining for HER2 in only 1 out of 6 cases with mucoepidermoid carcinomas. However, Weed et al (23), Cho et al (24) and Press et al (25) reported HER2 overexpression in 25, 36 and 38% of the studied cases.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Shang

Shui²,

Sheng³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

Abstract. The expression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) was analyzed in immunohistochemical preparations from 46 primary parotid mucoepidermoid carcinomas (MEC). For the cases with lymph node metastases, the receptor expressions were investigated in parallel samples, primary tumour and metastasis, from each patient (n=11). The goal was to evaluate whether any of these receptors are suitable as a target for radionuclide-based imaging and therapy. The HercepTest scoring was used for the analysis of both HER2 and EGFR expression (0, 1+, 2+ or 3+). EGFR overexpression (2+/3+) was found in 67.4% (31/46) of the primary tumours. Out of the 11 cases with evaluated paired samples, EGFR overexpression was observed in 81.8% (9/11) of the primary tumours and 72.7% (8/11) of the corresponding lymph node metastases. There was only one patient who had EGFR overexpression in the primary tumours which changed to negative in the lymph node metastases but no changes occurred reciprocally. The HER2 overexpression was only found in 4.3% (2/46) of the primary mucoepidermoid carcinoma and none of the lymph node metastases (0/11). EGFR and HER2 stainings were mainly found in the cell membranes. It was concluded that the majority of parotid mucoepidermoid carcinomas express EGFR strongly in their cell membranes and that lymph node metastases generally express EGFR to approximately the same extent as in the primary tumours. The stability in the EGFR expression is encouraging in the effort to develop radionuclide-based EGFR imaging agents. It is also possible that EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabelled antibodies) can be applied for the therapy of mucoepidermoid carcinoma.

show abstract

Section: Discussionmentioning

confidence: 97%

“…HER2 overexpression occurs in 0 to 38% of mucoepidermoid carcinoma (22)(23)(24)(25)(26)(27)(28). So far, no previous study has evaluated the EGFR and HER2 expression in metastases and compared such an expression with that of corresponding primary mucoepidermoid carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Shang

Shui²,

Sheng³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Previous studies with MMTV/ Ras mice have shown that MMTV is particularly active in parotid salivary glands and that this can lead to development of parotid tumors (33). In this regard, it is interesting to note that a certain proportion of human salivary gland tumors express elevated levels of ErbB2 (34)(35)(36)(37). Conversely, 14-3-3σ is downregulated through hypermethylation in certain salivary gland tumors (38).…”

Section: Discussion Loss Of 14-3-3s Is a Critical Event In Erbb2 Mammmentioning

confidence: 98%

Loss of the 14-3-3σ Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression

Chen

Zuo

et al. 2012

Cancer Discovery

View full text Add to dashboard Cite

is a putative tumor suppressor involved in cell-cycle progression and epithelial polarity. We demonstrate that loss of one or both copies of the conditional 14-3-3σ allele results in accelerated mammary and salivary tumorigenesis in mice expressing an activated erbB2 oncogene under the endogenous erbB2 promoter. Significantly, the majority of tumors bearing a single conditional 14-3-3σ allele lose expression of the remaining 14-3-3σ allele, which is associated with epigenetic methylation of the 14-3-3σ locus. In addition to accelerated tumor onset, in a mouse mammary tumor virusdriven ErbB2 tumor model, loss of 14-3-3σ results in enhanced metastatic phenotype that is correlated with loss of cellular junctions. Taken together, these results provide compelling evidence that 14-3-3σ is a potent tumor suppressor involved in ErbB2-driven breast cancer initiation and metastasis.siGNiFicaNce: 14-3-3σ has been identified as a normal mammary epithelial cell marker frequently downregulated during neoplastic development. Consistent with its potential role as a tumor suppressor, we demonstrate that targeted disruption of 14-3-3σ in a number of epithelial tissues can profoundly impact both the initiation and metastatic phases of ErbB2-mediated tumor progression through modulation of a number of distinct signaling networks. Cancer Discovery; 2(1); 68-81.

show abstract

“…Kärjä et al (1994) described positivity in 44% of cases, including malignant and benign tumors. However, other studies reported a rare expression of c-erbB-2 on these tumors (Kernohan et al, 1991;Shrestha et al, 1992).…”

Section: Discussionmentioning

confidence: 74%

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Bernardes¹,

Ramos-Jorge²,

Carmo³

et al. 2008

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY:The association among clinicopathological features and c-erbB-2 oncoprotein expression was evaluated in twentynine cases of intra-oral mucoepidermoid carcinoma (MEC). MEC was prevalent in the female gender (79.3%), tumors were more frequent in ages between 21 and 40 years (48.3%), and the palate was the most commonly affected site (72.4%). Microscopically, 27 cases (93.1%) were classified as low grade of malignancy. The c-erbB-2 expression was considered positive in 9 (31%) cases and no significant association (p>0.05) was found among protein expression and gender nor between patient age and site or histological grade of the lesion. c-erbB-2 expression in MEC may reflect intrisinc biologic properties of salivary gland neoplasms and may be linked to histogenesis and cellular differentiaton.

show abstract

Expression of c‐erbB‐2 oncoprotein in salivary gland tumours: An immunohistochemical study

Cited by 62 publications

References 18 publications

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

Loss of the 14-3-3σ Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Contact Info

Product

Resources

About